People · Operator
Named in public records as an officer, director or promoter · active 2007–2024 · Other, Healthtech, Other Health Care, Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nxthera Inc | — | Other | Series B | $87.1M | $342.4M | 2009 |
| Francis Medical, Inc. | — | Healthtech | Series B | $70.1M | $234.0M | 2018 |
| NeuMoDx Molecular, Inc. | — | Other Health Care | Series B | $54.8M | $444.0M | 2012 |
| Mirabilis Medica, Inc. | — | Other Health Care | Series A | $33.7M | $8.7M | 2007 |
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2018 |
| Koya Medical, Inc. | — | Healthtech | Series A | $11.0M | $209.4M | 2020 |
| Accord Biomaterials Inc | — | Biotechnology | Seed | $1.2M | $53.3M | 2010 |
Jan Garfinkle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jan Garfinkle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Williams | 2 | 10 |
| Josh Baltzell | 2 | 7 |
| William Burkoth | 2 | 5 |
| Michael Hoey | 2 | 4 |
| Nicole Walker | 2 | 4 |
| Andre De Bruin | 2 | 2 |
| Dinesh Patel | 1 | 13 |
| David Rubin | 1 | 11 |
| James Pavlik | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| David Adair | 1 | 7 |
| Kevin Fong | 1 | 6 |
| Sami Hamade | 1 | 6 |
| Edward Michael | 1 | 6 |
| Andrew Cleeland | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| David Auth | 1 | 5 |
| John Santini | 1 | 5 |
| J. ROBERT PAULSON | 1 | 4 |
| Gino DiSciullo | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.